Verily is teaming up with Colgate-Palmolive to conduct a study determining the new connections between oral health and overall health.
“Baseline Oral Health Study: UNCoVer the Connections to General Health” will be part of Verily’s ongoing Baseline Health Study. The new study will enroll patients ages 18 and older, with prediabetes, type 2 diabetes and/or cardiovascular disease for up to 18 months. The non-surgical periodontal therapy will be administered by co-investigators at the University of North Carolina at Chapel Hill Adams School of Dentistry.
“We’ve known for some time that oral health, cardiovascular disease and diabetes were interrelated,” said Rob Califf, MD, Head of Clinical Policy at Verily and Google Health. “The depth of biological measurement in the Baseline Health Study combined with the dental expertise of the UNC Adams School of Dentistry and Colgate will enable us to expand our knowledge base dramatically.”
Verily’s Baseline platform is an end-to-end evidence generation platform designed to accelerate scientific discovery and improve health outcomes. The company’s platform has been involved in a variety of different projects – many revolving around COVID-19.
In May of 2020, Verily announced it was using the Baseline COVID-19 Research Project to get a deeper understanding of antibody testing.
Earlier this year, Verily added another layer to Project Baseline – by launching a COVID-19 Immune Response Study with Janssen Research & Development.
Verily closed out 2020 announcing a $700 million investment that would help it accelerate key initiatives which include the Baseline Platform.